| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Cardiff Oncology, Inc. | Former Director | Stock Options | 125,317 | $325,824 | $2.60 | 09 Jun 2022 | Direct |
| OKYO Pharma Ltd | Director | Ordinary Shares | 16,670 | $25,005 | $1.50 | 15 Sep 2023 | Direct |
| Hepion Pharmaceuticals, Inc. | Chairman, Director | Stock Options | 99,563 | 19 Feb 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals, Inc. | 19 Feb 2024 | 1 | $0 | 4 | Chairman, Director | 21 Feb 2024, 20:01 |
| OKYO | OKYO Pharma Ltd | 15 Sep 2023 | 1 | +$25,005 | 4 | Director | 28 Sep 2023, 07:15 |
| CRDF | Cardiff Oncology, Inc. | 09 Jun 2022 | 9 | $0 | 4 | Former Director | 09 Jun 2022, 19:48 |
| OKYO | OKYO Pharma Ltd | 16 May 2022 | 0 | $0 | 3 | Director | 16 May 2022, 17:47 |
| CRDF | Cardiff Oncology, Inc. | 09 Mar 2022 | 1 | $0 | 4 | Director | 10 Mar 2022, 17:38 |
| ACUT | Accustem Sciences Inc. | 01 Dec 2021 | 0 | $0 | 3 | Director | 03 Dec 2021, 15:15 |
| CRDF | Cardiff Oncology, Inc. | 10 Jun 2021 | 1 | $0 | 4 | Director | 14 Jun 2021, 16:11 |
| HEPA | Hepion Pharmaceuticals, Inc. | 18 May 2021 | 1 | $0 | 4 | Director | 20 May 2021, 16:34 |